a series of long-awaited studies has found concrete evidence that the covid vaccines produce an appropriate, protective immune response in cancer patients, eliciting side effects no worse than those experienced by the general population.
the studies, to be presented this week at the annual congress of the
european society for medical oncology
, offer vital data on a vulnerable group that was excluded from vaccine trials and suggests a third “booster” shot may be necessary to enhance the level of protection of people currently fighting cancer.
“the esmo annual congress, held for the second time in a virtual format this year in an extra effort to protect our colleagues, has devoted significant efforts to making covid-19 a priority,”
said george pentheroudakis
, the chief medical officer of esmo. “the fact that we have received more than 90 abstracts on the topic, with excellent data, is a clear demonstration that this was the right thing to do.”
one of the key studies recruited 791 patients in the netherlands to determine the role, if any, cancer care plays in the efficacy of the moderna vaccine. patients were divided into four groups: those without cancer; those receiving immunotherapy for cancer; those receiving chemotherapy for cancer; and those receiving chemo-immunotherapy in combination for cancer. twenty-eight days after the second dose of the vaccine, researchers found adequate levels of antibodies in 84 per cent of patients receiving chemo, in 89 per cent of patients receiving chemo-immunotherapy and in 93 per cent receiving just immunotherapy.